SCHEMBL22290491

SCHEMBL22290491

Cn1c(=O)ccc2ccc(-c3csc(NC(=O)CN)n3)cc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ MAPT P10636 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ TRPA1 O75762 8/20 0.47
▸ HPGD P15428 1/20 0.46
▸ TRPV4 Q9HBA0 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ ABL1 P00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31173144 1.00 RAB9A (0.48) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL28676874 0.87 MEN1 (0.49) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL22290365 0.86 MAPT (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL31173238 0.86 RAB9A (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL22290415 0.83 RAB9A (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL31173493 0.83 RAB9A (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL22306416 0.81 HDAC3 (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL30315944 0.81 HDAC3 (0.47) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL22305784 0.80 RAB9A (0.43) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL22290738 0.79 KMT2A (0.47) RAB9AMEN1KMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885MEN1 1366/4885KMT2A 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback